September 8, 2023 01:30 PM EDTUpdated 03:32 PM
Pharma
Marketing

No­var­tis ad­justs busi­ness unit names in prepa­ra­tion for San­doz gener­ics and biosim­i­lars spin­off

Beth Snyder Bulik

Senior Editor

No­var­tis is mod­i­fy­ing its busi­ness units’ names to re­flect its full fo­cus on in­no­v­a­tive med­i­cines when San­doz spins off with gener­ics and biosim­i­lars lat­er this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times